Biopharmaceuticals Manufacturing Consumables Testing Market Worth $709.92 Million By 2025

The global biopharmaceuticals manufacturing consumables testing market size is expected to reach USD 709.92 million by 2025 at a 12.1% CAGR, according to a new report by Grand View Research, Inc. The market is driven by the growing need for an in-depth assessment of raw materials for the successful and rapid launch of the final product. Rising awareness pertaining to internal standards as well as external regulations in the biopharmaceutical industry is also aiding the market growth.

In the past few years, there has been a major paradigm shift from small chemical molecules to large biological molecules. As a result, the biopharmaceutical industry is geared toward exploring every aspect involved in the manufacturing process.

Regulatory and quality expectations for best quality raw materials and intermediates continue to increase. This, in turn, has pressurized vendors engaged in the manufacturing of excipients and raw materials to invest in standardizing functionality as well as establishing sophisticated processes to consistently address the needs of final product developers.

Click the link below:
https://www.grandviewresearch.com/industry-analysis/biopharmaceuticals-manufacturing-consumables-testing-market

Further key findings from the study suggest:

Based on service, compendial and multi-compendial testing held the largest share owing to demand from various manufacturers for raw materials that are compliant to regulatory standards
Testing services for Active Pharmaceutical Ingredients (APIs) accounted for the largest revenue share owing to the presence of a wide range of services in this segment
Presence of a large number of biologics manufacturing entities in the U.S. has resulted in North America dominating the global market in 2017. Rising competitive rivalry amongst market participants is also attributive for the large share of this region
Asia Pacific is expected to emerge as the fastest-growing regional market, fueled primarily by expansion of the contract service industry in several Asian countries. This is partly attributed to low operating costs in these nations
Key service providers in the market include Eurofins Scientific; Merck KGaA; Charles River; Agilent Technologies; and Catalent, Inc. These service providers are engaged in contract partnerships with major biopharmaceutical manufacturing companies.

Paper Diagnostics Market Worth $10.50 Billion By 2025

The global paper diagnostics market size is estimated to reach USD 10.50 billion by 2025, according to a new report by Grand View Research, Inc, rising at a CAGR of 8.0% during the forecast period. Increasing prevalence of diseases such as cancer, autoimmune diseases, and inflammatory diseases is one of the key factors expected to fuel the demand for novel and rapid diagnostics techniques, thereby driving the market during the forecast period. For instance, as per the American Cancer Society, in 2018, around 1.7 million new cancer cases are likely to be diagnosed and 609,640 individuals are poised to die due to cancer. The number of cancer cases is projected to rise by around 70.0% over the next two decades. This trend is anticipated to help the market gain momentum during the forecast period.

Rising R&D investments, technological advancements, and new product launches are the key growth strategies incorporated by companies to cater to rising needs. ARKRAY Inc.; Acon Laboratories, Inc.;Abbott; Bio-Rad Laboratories; Siemens healthcare; Abcam Plc; and Abingdon Health are some of the players focusing on new product development by rising R&D investments. For instance, in March 2017, ARKRAY Inc. launched saliva testing system, capable of measuring cariogenic bacteria, acidity & buffer capacity, occult blood, leukocyte & proteins, and ammonia from saliva. Moreover, in May 2017, ACON Laboratories, Inc. received U.S. FDA approval for its “Mission Urine Reagent Strips” for detection of Microalbumin and Creatinine.

Click the link below:
https://www.grandviewresearch.com/industry-analysis/paper-diagnostics-market

Further key findings from the report suggest:

Introduction of technologically advanced paper based diagnostic products, which offer sensitive and rapid results, is estimated to boost market growth over the forecast period
Development of paper-based ELISA for detection of autoimmune antibodies in body fluid is expected to bolster the demand for technologically advanced & upgraded lateral flow assays over the forecast period
Lateral flow assays held a significant share in the market in 2017, owing to wide application in disease diagnostics and associated advantages such as robust & rapid results, sensitivity, ease of use, and cost efficiency
Paper based diagnostic devices are widely used as point-of-care diagnostics. Increasing inclination towards these devices can be attributed to advent of wax patterning technology, facilitating greater flexibility and adaptability
In terms of application, the clinical diagnostics segment is likely to witness lucrative growth during the same period. Rising awareness regarding their benefits such as improved control and rapid results and growth prospects in area of nanomaterial & biomolecules are contributing to the growth of the segment
In 2017, North America was the most prominent regional market, owing to surging demand for self-testing devices coupled with well-established healthcare infrastructure
Market leaders are involved in R&D activities to develop accurate, cost efficient, and sensitive paper based microfluidics. Focus on mergers and acquisitions, consistent system upgradation through R&D investments and fund raising are some of the key strategies adopted by players.

Sickle Cell Anemia Testing & Screening Market Size Worth $340.71 Million By 2027

The global sickle cell anemia testing and screening market size is expected to reach USD 340.71 million by 2027, expanding at a CAGR of 5.44% from 2020 to 2027, according to a new report by Grand View Research, Inc. Hemoglobin S (HbS) is the causative factor for sickle cell disease and is currently the most prevailing disease or genetic abnormality across the globe, specifically across developing economies.

Sickle cell hemoglobin variants are inclusive of HbS, HbA, and HbC. Different tests have been developed to perform a clear distinction between all the three above-mentioned hemoglobin variants. Development of a deep learning framework designed to perform automated screening of sickle cell anemia in blood smear sample of patients via a smartphone microscope is set to open up new avenues for the market in the near future.

The market is moderately consolidated, wherein the key industry participants are striving to sustain market competition via partnerships, acquisitions, and expanding their business across newborn testing market space. Whereas, emerging companies are exploring potential of point-of-care tests to gain a competitive edge in the market.

A steep increase in the uptake of Hb electrophoresis and HPLC across government-initiated newborn screening programs and assessment studies have resulted in robust market penetration. This has, in turn, caught the attention of companies who are keen on modifying their existing product line, further amplifying consumption of the same.

Click the link below:
https://www.grandviewresearch.com/industry-analysis/sickle-cell-anemia-testing-screening-market

Further key findings from the report suggest:

By age group, several newborn screening programs have been employed across the globe to effectively manage the burden of this disease. These programs make use of different tests such as isoelectric focusing/ cellulose acetate electrophoresis, high-performance liquid chromatography (HPLC), and solubility tests
Based on technology, POC lateral flow assays are the most preferred testing methodologies in screening programs, forming the conventional means of testing
On the basis of sector type, government laboratories have witnessed maximum employment of sickle cell tests over the years
Government laboratories have actively participated in promoting the adoption of these tests by encouraging population-based sickle cell testing
Rise in the demand for federal and foundation funding to address healthcare disparities treatments and diagnosis of diseases, such as hemoglobinopathies and cystic fibrosis, is expected to drive the attention of the regulatory agencies.

Protein Purification And Isolation Market Worth $11.2 Billion By 2027

The global protein purification and isolation market size is expected to reach USD 11.2 billion by 2027, according to a new report by Grand View Research, Inc., registering a CAGR of 8.3% over the forecast period. An increase in technological advancements and investments for the development of structure-based drugs by both private and public research organizations are driving the demand for protein purification and isolation products.

Rising demand for the development of single-use products for purification due to the increasing need to classify novel protein-based ligands with high specificity and improved proteomics research is further driving the market growth. Another factor driving the adoption rate of protein purification techniques is the availability of an extensive range of innovative resins for various applications.

The key players operating in the market are Merck KGaA; Thermo Fisher Scientific; Qiagen; Sigma-Aldrich Co.; GE Healthcare; Agilent Technologies; Bio-Rad Laboratories, Inc.; Norgen Biotek Corporation; Abcam plc, and Promega Corporation. Market players are adopting strategies such as the expansion of product portfolio through R&D initiatives, mergers, acquisitions, and strategic collaborations to further strengthen their position in the market.

Click the link below:
https://www.grandviewresearch.com/industry-analysis/protein-purification-isolation-market

Further key findings from the report suggest:

The reagents segment is estimated to register a significant growth rate over the forecast period. This is attributed to its high usage in cell lysis and increased commercialization of advanced resins
On the basis of technology, chromatography emerged as the leading segment in 2019 owing to the availability of a varied range of products, enhanced results for complex protein purification, and high reliability
Drug screening is estimated to be the fastest-growing application segment over the forecast period owing to factors such as high efficacy and increasing R&D investments by manufacturers for the screening of novel drugs
Contract research organizations (CROs) are projected to witness a significant growth rate over the forecast period. This is attributed to increasing R&D investments and the growing number of preclinical trials outsourced by drug development firms
North America dominated the global protein purification and isolation market in 2019 owing to factors such as established research infrastructure, presence of major players, and technological advancements in the region
Asia Pacific is estimated to register the highest CAGR over the forecast period due to increasing economic stability, a growing number of CROs, and R&D activities in academic and research institutes.

Cord Blood Banking Services Market Size Worth $82.3 Billion By 2025

The global cord blood banking services market is expected to reach over USD 82.3 billion by 2025, growing at an estimated CAGR of around 11.9% from 2017 to 2025, according to a new study by Grand View Research, Inc. Key drivers of the market include increasing application of stem cell therapies in disease treatment, and rising prevalence of life threatening genetic disorders.

Moreover, increasing spending capacity is fueling the demand for advanced healthcare facilities including disease prevention and treatment. As a result, parents are increasingly demanding CBB services to ensure safety of their child’s future. Furthermore, private players are practicing marketing activities which are creating awareness about the availability of the CBB services and their benefits.

In addition, governments worldwide are promoting public CBB to develop ethnically diverse cord blood repository which would increase the chances of finding suitable human leukocyte antigen (HLA) match for the patients. As a result, availability of the ethnically rich CB repository coupled with anticipated rise in the stem cell therapies and bone marrow transplants, is expected to spur the CBB services during the forecast period.

Click the link below:
https://www.grandviewresearch.com/industry-analysis/cord-blood-banking-services-market

Further Key Findings From the Report Suggest:

Private bank segment accounted for the largest revenue share in 2016. High cost of collection, processing, and storage along with the maximum awareness created by marketing activities practiced by the players resulted in large revenue share of private banks across the globe.
Rising government support and no storage and collection costs are the major factors anticipated to drive the public banking sector during the forecast period from 2017 to 2025 with highest CAGR.
North America dominated the global market and was followed by Europe in 2016. Dominance of North America is owing to government support and high rate of stem cell therapy in the U.S. and Canada.
Moreover, high awareness and insurance coverage of cord blood banking and stem cell therapies is further boosting the growth of the market in North America
Densely populated emerging countries of Asia Pacific are anticipated to show significant growth during the forecast period from 2017 to 2025.
Factors such as increasing investment by global players, government support and rising healthcare expenditure are anticipated to boost the cord blood banking services market in Asia Pacific
Global CBB services sector is highly fragmented with presence of many private and public players. Few global players operate in various geographies through subsidiaries. While local players are operating independently in respective geographies.
Key players of this market include China Cord Blood Corporation, Cord Blood America, Inc., CBR Systems, Inc., Cordlife Group Limited, Cryo-Cell International, Inc., Cryo-Save AG, Lifeforce Cryobanks, National Cord Blood Program, ViaCord, Inc. and Virgin Health Bank

Cancer Stem Cells Market Worth $1.6 Billion By 2025

The global cancer stem cells market size is expected to reach USD 1.6 billion by 2025, according to a new report by Grand View Research, Inc., expanding at a CAGR of 9.98% during the forecast period. Although stem cell-based cancer treatment is facing regulatory and ethical challenges, the market is growing worldwide. With increasing awareness about these cells, there is steady growth in the R&D for the development of effective and novel treatment methods based on stem cells.

Furthermore, continuous rise has been observed in the number of research studies on cancer stem cells (CSCs) being published. These studies have helped healthcare professionals gain insights into CSCs biology and their signaling pathways. This is expected to create tremendous growth prospects for the market.

Furthermore, improvements in experimental approaches, in particular, in vitro assay systems have enabled scientists to establish relationship between different cell types in a tumor and their microenvironment. This has led to development of a broad therapeutic portfolio for CSCs and their associated key pathways for restricting growth of the tumor and providing improved clinical outcome.

Click the link below:
https://www.grandviewresearch.com/industry-analysis/cancer-stem-cells-market

Further key findings from the report suggest:

The anti-CSC therapeutics segment accounted for a significant share owing to increasing R&D activities for the development of novel therapeutics
Anti-CSCs therapeutics/agents include agents that target key pathways, surface markers, immuno-evasion & tumor microenvironment, along with nanoparticle-based therapies. As key pathways play a major role in tumor regulation, pathway inhibitors captured the largest share owing to the presence of a broad portfolio of products under pipeline
With rising prevalence of bladder cancer, the segment is expected to exhibit the highest CAGR of 10.47% during the forecast period
North America held the largest share in 2016 owing to presence of a large number of facilities in the U.S. that offer stem cell services
Asia Pacific is likely to emerge as the fastest growing regional market owing to increasing investments by various agencies to accelerate research activities in Asian countries
Some of the prominent players in the market are Thermo Fisher Scientific, Inc.; AbbVie, Inc.; Merck KGaA; Bionomics; and Lonza.

Cancer Immunotherapy Drug Discovery Outsourcing Market Worth $1.7 Billion by 2025

The global cancer immunotherapy drug discovery outsourcing market size is projected to reach USD 1.7Billion by 2025, according to a new report by Grand View Research, Inc., rising at a CAGR of 13.5% during the forecast period. Increasing prevalence of cancer and rising mortality associated with cancer, along with growing development in the field of cancer immunotherapy, are anticipated to stimulate the growth of the market.

Blue and white pill inside immersive interface over blue red background with atomic grid. Concept of hi tech in medicine. 3d rendering toned image

In order to maintain pace with the increasing competition in the cancer therapeutics industry, pharmaceutical companies spend 2.5% more than other high tech industries in the in-house R&D. Hence, they are swiftly shifting toward the outsourcing of drug discovery in order to achieve lower in-house R&D costs.

Additionally, favorable tax credit allows pharmaceutical companies to appropriately plan their global projects with a reputed CRO and therefore, receive benefits and reduce problems associated with taxation authorities or other bodies administering such incentive programs.

Several new molecules for cancer immunotherapy and new immunotherapeutic options, such as tumor-infiltrating lymphocytes, checkpoint inhibitors immunomodulators, and CAR-T cell therapy, have been introduced. Some are in the pipeline and are being tested for their ability to provide better cancer treatment

Click the link below:
https://www.grandviewresearch.com/industry-analysis/cancer-immunotherapy-drug-discovery-outsourcing-market

Further key findings from the report suggest:

Monoclonal antibodies emerged as the largest segment in 2017 because of increasing regulatory approvals and higher efficacy
Target identification and validation accounted for the largest share in the global market owing to higher costs incurred and increased investments in new drug development
North America dominated the market with the largest share in 2017. Rising incidence of cancer and increasing demand for novel technologies are facilitating the dominance of the region during the forecast period
Some of the key players are Covance, Inc.; Explicyte; Aquila BioMedical; Horizon Discovery Group PLC; Crown Bioscience, Inc.; Promega Corporation; HD Biosciences Co., Ltd.; BPS Bioscience, Inc.; Genscript Biotech Corporation; DiscoverX Corporation; Celentyx Ltd.; ImmunXperts SA; Personalis, Inc.; STC Biologics; and Molecular Imaging, Inc. dominated the cancer immunotherapy drug discovery outsourcing market.

Mammalian Polyclonal IgG Antibody Market Worth $1.21 Billion By 2025

The global mammalian polyclonal IgG antibody market size is expected to reach USD 1.21 billion by 2025 expanding at a CAGR of 5.1%, according to a new report by Grand View Research, Inc. Advantages over other forms of antibodies, increasing global R&D investments, and rising adoption of novel diagnostic procedures are factors driving the market. Global rise in chronic and infectious diseases also play a key role in propelling the market growth.

Polyclonal antibodies are the most preferred choice in routine laboratory tests, such as ELISA, microarray assays, western blotting, flow cytometry, and immunohistochemistry. Production of these does not require skilled professionals and large batches can be produced as per client requirements. A polyclonal antibody can recognize multiple antigens on one epitope and therefore can be utilized in the study of various diseases ranging from cancer to metabolic diseases. Denatured proteins are often detected with the use of polyclonal antibodies.

Thus, increasing use of these products in the treatment of several chronic diseases is also anticipated to fuel growth in the near future. Rising investments by major pharma companies, such as Novartis and Roche, for the development of therapeutic antibodies and novel diagnostic techniques and for QC purposes are also driving the market growth. For instance, R&D investments by top 10 biotech companies increased from USD 8.2 billion in 2010 to USD 10.2 billion in 2016, accounting for a 13% increase.

Click the link below:
https://www.grandviewresearch.com/industry-analysis/mammalian-polyclonal-igg-antibody-market

Further key findings from the report suggest:

Large amount of polysera obtained from goats and predominant use of these animals as hosts has contributed to its large market share in 2017
Metabolic biomarkers are expected to hold the largest market share during the forecast period due to growing prevalence of chronic diseases, such as cardiovascular diseases (CVDs) and cancer
ELISA tests provide accurate diagnosis of disease, such as AIDS, Lyme disease, syphilis, pernicious anemia, Rocky Mountain spotted fever, squamous cell carcinoma, chickenpox, shingles, and other bacterial and viral infections, than other antibody-based assays contributing to its high market share
Availability of technologically advanced equipment and presence of major market players has attributed to the North American region garnering large market share
Asia Pacific is anticipated to gain significant market share in near future due to rising R&D investment and presence of target population
Few key companies in the global mammalian polyclonal IgG antibody market include Abcam PLC; Bio-Rad Laboratories, Inc.; Thermo Fisher Scientific; Merck KgaA; Cell Signaling Technologies, Inc.; and Hoffmann-La Roche Ltd.

Immunoprotein Diagnostic Testing Market Worth $10.3 Billion By 2025

According to a recent report published by Grand View Research Inc., product approval initiatives are likely to accelerate immunoprotein diagnostic testing market expansion.

According to a report, “Immunoprotein Diagnostic Testing Market Size, Share & Trends Analysis By Type (Complement System Proteins, Free Light Chain, Haptoglobin, Immunoglobulin), By Technology, By Application, And Segment Forecasts, 2018 – 2025”, published by Grand View Research, Inc. The global immunoprotein diagnostic testing market size is expected to reach USD 10.3 billion by 2025, registering a staggering CAGR, as per a new report by Grand View Research Inc. The market demand can be attributed to the rising incidence of chronic diseases.

According to a 2017 research report by the American Heart Association, nearly 790,000 people suffer heart attack every year in the U.S. Furthermore, stroke is responsible for 1 in every 20 deaths in the country. Hence, WHO is undertaking initiatives to decrease the risk and occurrence of cardiovascular diseases. Such factors are driving the demand for immunoprotein diagnostics and are expected to rise during the forecast period in order to facilitate rapid diagnosis.

According to WHO, nearly 1.69 million deaths were registered due to lung cancer in 2015, worldwide. As a result, fast and accurate diagnosis of chronic diseases has become crucial to reduce the growing mortality rate. Immunoprotein diagnostic devices and reagents have proven to be highly effective in detecting chronic diseases.

Technological advancements in immunoprotein diagnostics have led to the introduction of novel products. For instance, LIAISON XL, manufactured by DiaSorin, is a fully automated chemiluminescence analyzer that facilitates complete sample processing. It also measures and evaluates testing samples, thereby, enhancing the efficiency and throughput of the system.

Click the link below:
https://www.grandviewresearch.com/industry-analysis/immunoprotein-diagnostic-testing-industry

Immunoprotein Diagnostic Testing Market Highlights

Immunoglobulin tests held the test type segment in 2016 due to its widespread adoption by healthcare professionals to monitor the functioning of a patient’s immune system in autoimmune or infectious diseases.
C-Reactive Protein (CRP) tests are gaining huge traction as they can assist in monitoring the treatment effectiveness for infectious diseases and cancer. CPR tests also accounted for a significant market share in 2016.
On the basis of application, infectious disease testing led the market in 2016, followed by oncology testing. Infectious disease testing segment growth can be ascribed to the rising prevalence of chronic infectious diseases, such as HIV/AIDS. Enzyme-based immunoassays are gaining popularity as they are considered rapid testing techniques for disease identification.
Enzyme-based Immunoassay (EIA) led the market, accounting for the largest revenue share in 2016. Human Complement C3 ELISA Kit developed by Abcam uses EIA technology for diagnosis.

Reporter Gene Assay Market Size Worth $9.0 Billion By 2027

The global reporter gene assay market size is expected to reach USD 9.0 billion by 2027 registering a CAGR of 8.1%, according to a new report by Grand View Research, Inc. Reporter genes have significant demand as they are increasingly being used in studying gene expression and across several research studies in the fields of biochemistry, molecular biology, and pharmaceuticals. Reporter genes also play a pivotal role in quantifying the regulatory potential of unknown DNA sequences.

Rising penetration of these assays in diagnostic applications and their utility in understanding signal transduction pathways is expected to propel the market growth. Promega Corporation has developed vectors that can be used in investigation of signaling pathways. The company has also developed rapid response reporters to enhance the signal to background ratio.

Several other prominent market players also offer a strong product portfolio for luciferase assays. For instance, ThermoFisher Scientific offers a wide range of luciferase and Chemiluminescent assays to monitor the reporter activity. Moreover, presence of key market players such as Promega Corporation in developing economies is expected to drive the demand in this market.

Click the link below:
https://www.grandviewresearch.com/industry-analysis/reporter-gene-assay-market

Further key findings from the report suggest:

Luciferase assays accounted for the highest revenue share in 2019 and is anticipated to retain its leading position throughout the forecast period
This is because luciferase enables precise measurement of signal maintaining consistency of the outcomes
In vitro studies application segment is projected to register the fastest CAGR of 8.3% from 2020 to 2027 owing to increasing need for rapid screening
Cell signaling pathways subsegment displayed the highest contribution to the clinical applications segment in 2019 owing to rise in adoption of reporter assays for GPCR signaling investigations and for screening chemicals that cause signaling disruption
These protocols are majorly employed in drug discovery programs, which has largely contributed to the growth of this segment in the global market throughout the forecast period
Hospital & diagnostic laboratories end-use segment is expected to register the highest CAGR from 2020 to 2027
North America accounted for the highest revenue share in 2019 owing to high penetration of cell-based assay technologies in the regional market
Asia Pacific is expected to witness the fastest CAGR from 2020 to 2027 due to rise in the number of research investigations that are focused on use of reporter genes for regulation of several disorders